Genotypic and phenotypic characterisation of respiratory syncytial virus after nirsevimab breakthrough infections: a large, multicentre, observational, real-world study

• Published in: The Lancet infectious diseases 2024-10
• Main Authors: Reslan, Alawiya, Casalegno, Jean-Sébastien, Chollet, Lionel, Pillet, Sylvie, Tremeaux, Pauline, Salmona, Maud, Imbert-Marcille, Berthe-Marie, Larrat, Sylvie, Marot, Stéphane, Stephan, Valentin, Brichler, Ségolène, Jaffar-Bandjee, Marie-Christine, Francois, Catherine, Hartard, Cédric, Dos Santos, Georges, Simon-Loriere, Etienne, Schwartz, Olivier, Buchrieser, Julian, Pawlotsky, Jean-MiIchel, Lemoine, Frédéric, Audureau, Etienne, Rameix-Welti, Marie-Anne, Zemali, Naël, Moisan, Alice, Zavaoarisaina, Zakasoa-Mbololona, Avettand-Fenoel, Véronique, Guillaume, Clémence, Mchantaf, Gilbert, Marie, Victoria, Bret, Laurent, Lesne, Fabien, Alidjinou, Kazali, de Pontual, Loic, Aupiais, Camille, Perrier, Marine, Jatteau, Pierre, Fofana, Djeneba, Cocherie, Théophile, Soulié, Cathia, Faisant, Anne, Tournegros, Caroline, Bourlet, Thomas, Bouthry, Elise, Warnakulasuriya, Fairly, Jaffar, Marie-Christine, Heaugwane, Diana, Azemar, Benjamin, Castelain, Sandrine, Rames, Cinthia, Bécourt, Arnaud, Foulongne, Vincent, Domitien, Léa, Handala, Lynda, Gaudy-Graffin, Catherine, Crémadés, Agathe, Gabassi, Audrey, Néré, Marie-Laure, Bonacorsi, Stéphane, Ouldali, Naim, Reslan, Alawyia, Bourret, Jérome, Yab, Emilie, Enouf, Vincent, Donati, Flora, Prot, Matthieu, Jeyarajah, Banujaa, Dossou, Nefert Candace, Vabret, Astrid, Rodriguez, Christophe, Cappy, Pierre, Soulier, Alexandre, Ader, Mohamed, Natella, Pierre-André, Fagour, Laurence, Schapira, Anne-Julie, Leveque, Nicolas, Morton Fauche, Claire, Castain, Louise, Rodallec, Audreay, Gras-le Guen, Christele, Chauvire-Drouard, Anne, Deback, Claire, Solis, Morgane, Gaitan, Léa, Mirand, Audrey, Thibault, Vincent, Trémeaux, Pauline, Claudet, Isabelle, Pucelle, Mélanie, Vellas, Camille, Veyrenche, Nicolas, Gaymard, Alexandre, Kombou, Jose
• Format: Article
• Language: English
• Subjects: Human health and pathology; Life Sciences; Pulmonology and respiratory tract
• ISSN: 1473-3099; 1474-4457; 1474-4457
• DOI: 10.1016/S1473-3099(24)00570-X

Nirsevimab, a long-acting monoclonal antibody, has been approved for the prevention of respiratory syncytial virus (RSV) infection in infants. In France, more than 210 000 single doses were administered in infants younger than 1 year during the 2023–24 season. In this context, the selection and spread of escape variants might be a concern. Here, we aimed to characterise RSV associated with breakthrough infection. We did a multicentre, national, observational study in France during the 2023–24 RSV season in RSV-infected infants (aged